Hanmi Faces Another Licensee U-Turn, This Time Janssen On Obesity/Diabetes Drug

 
• By Jung Won Shin

Janssen has returned the rights to an obesity/diabetes drug to originator Hanmi, after Phase II studies failed to achieve glycemic control targets and reflecting development difficulties in the sector. This is the fourth time for the Korean firm to face a U-turn of licensed out compounds. 

Desperate businessmen
Janssen Drops Hanmi's GLP-1/GCG peptide As Glycemic Control Targets Unmet

More from South Korea

More from Focus On Asia